{ "items": [ "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model\n

\n \n \n \n \n\n \n \n \n

Dobinson HC. et al, (2017), Clinical Infectious Diseases, 64, 1066 - 1073

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year.\n

\n \n \n \n \n\n \n \n \n

Winslow RL. et al, (2017), JAMA, 317, 1075 - 1077

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial\n

\n \n \n \n \n\n \n \n \n

Iro MA. et al, (2017), Vaccine, 35, 395 - 402

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy\n

\n \n \n \n \n\n \n \n \n

Pace D. et al, (2016), Vaccine, 34, 6350 - 6357

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Psychoeducation and online mood tracking for patients with bipolar disorder: A randomised controlled trial\n

\n \n \n \n \n\n \n \n \n

Bilderbeck AC. et al, (2016), Journal of Affective Disorders, 205, 245 - 251

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Non-specific immunological effects of selected routine childhood immunisations: systematic review.\n

\n \n \n \n \n\n \n \n \n

Kandasamy R. et al, (2016), BMJ, 355

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a\n

\n \n \n \n \n\n \n \n \n

Darton TC. et al, (2016), PLOS Neglected Tropical Diseases, 10, e0004926 - e0004926

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n The impact of administration of conjugate vaccines containing cross reacting material on Haemophilus influenzae type b antibody responses in infants: A systematic review and meta-analysis of randomised controlled trials.\n

\n \n \n \n \n\n \n \n \n

Voysey M. et al, (2016), Vaccine, 34, 3986 - 3992

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children: study protocol for an individual participant data meta-analysis of randomised controlled trials\n

\n \n \n \n \n\n \n \n \n

Voysey M. et al, (2016), BMJ Open, 6, e011680 - e011680

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.\n

\n \n \n \n \n\n \n \n \n

Tr\u00fcck J. et al, (2016), Pediatr Infect Dis J, 35, 787 - 793

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n The predicted persistence and kinetics of antibody decline 9 years after pre-school booster vaccination in UK children\n

\n \n \n \n \n\n \n \n \n

Voysey M. et al, (2016), Vaccine, 34, 4221 - 4228

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.\n

\n \n \n \n \n\n \n \n \n

Milligan ID. et al, (2016), JAMA, 315, 1610 - 1623

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Factors influencing women's attitudes towards antenatal vaccines, group BStreptococcusand clinical trial participation in pregnancy: an online survey\n

\n \n \n \n \n\n \n \n \n

McQuaid F. et al, (2016), BMJ Open, 6, e010790 - e010790

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age\n

\n \n \n \n \n\n \n \n \n

Snape MD. et al, (2016), The Pediatric Infectious Disease Journal, 35, e113 - e123

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells.\n

\n \n \n \n \n\n \n \n \n

Voysey M. et al, (2016), Vaccine, 34, 1657 - 1664

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults\n

\n \n \n \n \n\n \n \n \n

Lazarus R. et al, (2016), PLOS ONE, 11, e0165384 - e0165384

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2\u2008\u00d7\u20082 factorial randomised trial\n

\n \n \n \n \n\n \n \n \n

Geddes JR. et al, (2016), The Lancet Psychiatry, 3, 31 - 39

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Factors affecting the causality assessment of adverse events following immunisation in paediatric clinical trials: An online survey.\n

\n \n \n \n \n\n \n \n \n

Voysey M. et al, (2015), Vaccine, 33, 7203 - 7210

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Mixed effects approach to the analysis of the stepped wedge cluster randomised trial - accounting for the confounding effect of time\n

\n \n \n \n \n\n \n \n \n

Nickless A. et al, (2015), Trials, 16

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults\n

\n \n \n \n \n\n \n \n \n

Green CA. et al, (2015), BMJ Open, 5, e008748 - e008748

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n" ], "more": "\n\n \n \n Load More\n \n \n\n", "msg": "" }